The International Neuroblastoma Risk Group (INRG) classification system: An INRG task force report

Journal of Clinical Oncology

Volumn 27, Issue 2, 2009, Pages 289-297

  Cohn, Susan L ^a   Pearson, Andrew D J ^b   London, Wendy B ^b   Monclair, Tom ^b   Ambros, Peter F ^b   Brodeur, Garrett M ^b   Faldum, Andreas ^b   Hero, Barbara ^b   Iehara, Tomoko ^b   Machin, David ^b   Mosseri, Veronique ^b   Simon, Thorsten ^b   Garaventa, Alberto ^b   Castel, Victoria ^b   Matthay, Katherine K ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; CANCER STAGING; CHILD; CHROMOSOME 11Q; EUROPE; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFANT; JAPAN; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NORTH AMERICA; ONCOGENE; ONCOGENE MYCN; PLOIDY; PRIORITY JOURNAL; RISK MANAGEMENT; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; AGE; CLASSIFICATION; COHORT ANALYSIS; GENETICS; INTERNATIONAL CLASSIFICATION OF DISEASES; METABOLISM; METASTASIS; PATHOLOGY; PRESCHOOL CHILD; REGRESSION ANALYSIS; RISK FACTOR;

FERRITIN; LACTATE DEHYDROGENASE;

AGE FACTORS; CHILD, PRESCHOOL; COHORT STUDIES; FERRITINS; HUMANS; INFANT; INTERNATIONAL CLASSIFICATION OF DISEASES; L-LACTATE DEHYDROGENASE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROBLASTOMA; REGRESSION ANALYSIS; RISK FACTORS;

EID: 58249093955     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.6785     Document Type: Article

References (31)

1. Maris JM, Hogarty MD, Bagatell R, et al: Neuroblastoma. Lancet 369:2106-2120, 2007
2. Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3:203-216, 2003
3. Cecchetto G, Mosseri V, De Bernardi B, et al.: Surgical risk factors in primary surgery for localized neuroblastoma: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 23:8483-8489, 2005
4. Kushner BH, Cohn SL: Intermediate-risk neuroblastoma, in Cheung N-KV, Cohn SL (eds): Neuroblastoma. Heidelberg, Germany, Springer-Verlag, 2005, pp 131-137
5. Attiyeh EF, London WB, Mosse YP, et al: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243-2253, 2005
6. Caron H, van Sluis P, de Kraker J, et al: Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334:225-230, 1996
7. Bown N, Cotterill S, Lastowska M, et al: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340:1954-1961, 1999
8. Brodeur GM, Seeger RC, Barrett A, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874-1881, 1988
9. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
10. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
11. Maris JM, Weiss MJ, Guo C, et al: Loss of heterozygosity at 1p36 independently predicts for disease progression, but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group Study. J Clin Oncol 18:1888-1899, 2000
12. Shimada H, Chatten J, Newton WA, Jr., et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984
13. Shimada H, Ambros IM, Dehner LP, et al: The International Neuroblastoma Pathology Classification (the Shimada System). Cancer 86:364-372, 1999
14. Monclair T, Brodeur GM, Ambros PF, et al: The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol doi:10.1200/JCO.2008.16.6876
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Cox DR: Regression models and life-tables. JRSSB 34:187-220, 1972
17. Segal MR: Regression trees for censored data. Biometrics 44:35-47, 1988
18. Davis RB, Anderson JR: Exponential survival trees. Stat Med 8:947-961, 1989
19. Leblanc M, Crowley J: Survival trees by goodness of split. J Am Stat Assoc 88:457-467, 1993
20. London WB, Castleberry RP, Matthay KK, et al: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23:6459-6465, 2005
21. London WB, Shimada H, d'Amore ES, et al: Age, tumor grade, and MKI are independently predictive of outcome in neuroblastoma. Proc Am Soc Clin Oncol 25:540s, 2007 (abstr 9558)
22. Simon T, Hero B, Benz-Bohm G, et al: Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer 50:965-969, 2008
23. Castleberry RP, Shuster JJ, Smith EI: The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma: Member Institutions of the Pediatric Oncology Group. J Clin Oncol 12:2378-2381, 1994
24. Schmidt ML, Lal A, Seeger RC, et al: Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 23:6474-6480, 2005
25. George RE, London WB, Cohn SL, et al: Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months of age with disseminated neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 23:6466-6473, 2005
26. Matthay KK, Perez C, Seeger RC, et al: Successful treatment of Stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group Study. J Clin Oncol 16:1256-1264, 1998
27. Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:581-591, 1991
28. Look AT, Hayes FA, Nitschke R, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311:231-235, 1984
29. Ladenstein R, Ambros IM, Potschger U, et al: Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med Pediatr Oncol 36:83-92, 2001
30. Vandesompele J, Baudis M, De Preter K, et al: Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 23:2280-2299, 2005
31. Schleiermacher G, Michon J, Huon I, et al: Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer 97:238-246, 2007